Vedanta Biosciences is touting positive new Phase 2 results for a microbe-based treatment for C. difficile, the fourth major biotech to take this approach toward the life-threatening bacterial disease.
People who received a relatively high dose of Vedanta’s drug, which is made from eight strains of bacteria, had 80% fewer recurrences of C. diff than people who received a placebo, the company said Tuesday. The absolute difference in the proportion of people whose C. difficile infections recurred was more than 37 percentage points.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
